文献速递白血病淋巴瘤

1995至2009年全球儿童白血病生存率按亚型、年龄和性别的比较(CONCORD-2):基于53个国家198个登记处89828名儿童个体数据的群体研究

Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.
PubMed 文献 · Lancet Haematol · 2017-04-11

CONCORD-2项目分析了53个国家198个登记处89828名0-14岁白血病儿童的个体数据,估算1995-99、2000-04和2005-09三个诊断时期的5年净生存率。结果显示儿童白血病生存率的全球差异随时间缩小但仍很宽,淋系白血病2005-09年年龄标化生存率从哥伦比亚卡利的52.4%到德国登记处的91.6%,AML从保加利亚的33.3%到德国登记处的78.2%;1-4岁和5-9岁儿童生存率最高,婴儿最低,男女间无系统性差异。

要点

  • 2005-09年淋系白血病年龄标化5年净生存率从哥伦比亚卡利的52.4%到德国登记处的91.6%
  • 2005-09年AML年龄标化5年净生存率从保加利亚的33.3%到德国登记处的78.2%
  • 1-4岁和5-9岁儿童生存率最高,婴儿(<1岁)最低,男女间无系统性差异

核心结论

  • 儿童白血病生存率的全球不平等随时间缩小,但ALL和AML的差距仍然很宽。

研究设计与样本

  • 基于人群的群体研究,纳入1995年1月1日至2009年12月31日诊断、随访至2009年12月31日的0-14岁白血病儿童,来自53个国家198个登记处共89828名儿童。
  • 按诊断时期(1995-99、2000-04、2005-09)、性别和诊断年龄(<1、1-4、5-9、10-14岁)估算5年净生存率,并对前体细胞ALL和AML进行年龄标化净生存率比较。

主要发现

  • 1995-99年全部淋系白血病合计的5年年龄标化净生存率从中国登记处的10.6%(95%CI 3.1-18.2)到奥地利的86.8%(81.6-92.0)。
  • 2005-09年淋系白血病年龄标化5年净生存率从哥伦比亚卡利的52.4%(95%CI 42.8-61.9)到德国登记处的91.6%(89.5-93.6)。
  • 2005-09年AML年龄标化5年净生存率从保加利亚的33.3%(95%CI 18.9-47.7)到德国登记处的78.2%(72.0-84.3)。
  • 前体细胞ALL的生存率与全部淋系白血病合计非常接近,变异情况相似。
  • 在多数国家,2000-04至2005-09年间AML生存率的改善大于ALL。

关键数值与推荐

  • 5年净生存率定义为诊断后至少存活5年的概率,已控制其他原因死亡(背景死亡率)。
  • 血液系统恶性肿瘤按国际肿瘤学疾病分类第三版形态学编码定义。
  • 排除了数据可靠性判定较低、仅含淋巴瘤的登记处数据,以及可分析儿童数据少于10例的国家数据。
  • 排除了出生日期、诊断日期或末次已知生命状态缺失的记录。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. METHODS: Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995-99, 2000-04, and 2005-09), sex, and age at diagnosis (<1, 1-4, 5-9, and 10-14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). FINDINGS: We analysed data from 89 828 children from 198 registries in 53 countries. During 1995-99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1-18·2) in the Chinese registries to 86·8% (81·6-92·0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005-09, when age-standardised survival for lymphoid leukaemias ranged from 52·4% (95% CI 42·8-61·9) in Cali, Colombia, to 91·6% (89·5-93·6) in the German registries, and for AML ranged from 33·3% (18·9-47·7) in Bulgaria to 78·2% (72·0-84·3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000-04 and 2005-09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1-4 and 5-9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls. INTERPRETATION: Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood cancer survival. FUNDING: Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Bonaventure A, Harewood R, Stiller CA, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017. PMID: 28411119. doi:10.1016/S2352-3026(17)30052-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。